EA013326B1 - Вакцина - Google Patents
Вакцина Download PDFInfo
- Publication number
- EA013326B1 EA013326B1 EA200702079A EA200702079A EA013326B1 EA 013326 B1 EA013326 B1 EA 013326B1 EA 200702079 A EA200702079 A EA 200702079A EA 200702079 A EA200702079 A EA 200702079A EA 013326 B1 EA013326 B1 EA 013326B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nru
- vaccine
- protein
- immunogenic fragment
- fragment
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 247
- 239000012634 fragment Substances 0.000 claims abstract description 99
- 230000002163 immunogen Effects 0.000 claims abstract description 78
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 34
- 231100000590 oncogenic Toxicity 0.000 claims abstract description 23
- 230000002246 oncogenic effect Effects 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 101710132701 Protein L1 Proteins 0.000 claims description 49
- 208000015181 infectious disease Diseases 0.000 claims description 48
- 239000002671 adjuvant Substances 0.000 claims description 30
- 230000028993 immune response Effects 0.000 claims description 30
- 238000002255 vaccination Methods 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 230000002708 enhancing effect Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 241000701806 Human papillomavirus Species 0.000 claims description 8
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 229940124856 vaccine component Drugs 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 150000003432 sterols Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 abstract 5
- 229960002566 papillomavirus vaccine Drugs 0.000 abstract 2
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 27
- 239000000902 placebo Substances 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 25
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 230000001667 episodic effect Effects 0.000 description 17
- 150000007949 saponins Chemical class 0.000 description 16
- 229930182490 saponin Natural products 0.000 description 15
- 235000017709 saponins Nutrition 0.000 description 15
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000002380 cytological effect Effects 0.000 description 11
- 208000037581 Persistent Infection Diseases 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100040294 Protein unc-50 homolog Human genes 0.000 description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 101710197851 B1 protein Proteins 0.000 description 4
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 101710116895 DNA-binding protein H-NS Proteins 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 101710132617 Protein B1 Proteins 0.000 description 3
- 101710170630 Ribonucleoside-diphosphate reductase 1 subunit alpha Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
- 201000004201 anogenital venereal wart Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 2
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229940031416 bivalent vaccine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002573 colposcopy Methods 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940031351 tetravalent vaccine Drugs 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 101150011812 AADAC gene Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100022653 Histone H1.5 Human genes 0.000 description 1
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220279167 rs1064793333 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67482905P | 2005-04-26 | 2005-04-26 | |
| GB0509010A GB0509010D0 (en) | 2005-05-03 | 2005-05-03 | Vaccine |
| PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
| PCT/EP2006/003918 WO2006114312A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702079A1 EA200702079A1 (ru) | 2008-04-28 |
| EA013326B1 true EA013326B1 (ru) | 2010-04-30 |
Family
ID=36992675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702079A EA013326B1 (ru) | 2005-04-26 | 2006-04-24 | Вакцина |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090181052A1 (enExample) |
| EP (1) | EP1877086A2 (enExample) |
| JP (1) | JP2008539184A (enExample) |
| KR (1) | KR20080005585A (enExample) |
| AR (1) | AR054259A1 (enExample) |
| AU (1) | AU2006239422A1 (enExample) |
| CA (1) | CA2606092A1 (enExample) |
| EA (1) | EA013326B1 (enExample) |
| MX (1) | MX2007013472A (enExample) |
| NO (1) | NO20075194L (enExample) |
| SG (1) | SG159525A1 (enExample) |
| WO (1) | WO2006114312A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| RS53607B1 (sr) * | 2008-07-31 | 2015-04-30 | Glaxosmithkline Biologicals S.A. | Vakcina protiv hpv |
| AU2009348078B2 (en) * | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| WO2012177970A1 (en) | 2011-06-24 | 2012-12-27 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
| US11638754B2 (en) | 2020-02-14 | 2023-05-02 | Merck Sharp & Dohme Llc | HPV vaccine |
| US20230048144A1 (en) | 2021-08-06 | 2023-02-16 | Merck Sharp & Dohme Llc | Hpv vaccine |
| MX2024002144A (es) | 2021-08-19 | 2024-04-23 | Merck Sharp & Dohme Llc | Nueva nanoparticula lipidica termostable y metodos de uso de la misma. |
| TW202513091A (zh) | 2023-06-09 | 2025-04-01 | 美商默沙東有限責任公司 | 用於人類乳突病毒疫苗之奈米乳液佐劑組合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
| WO2002070004A2 (en) * | 2001-03-07 | 2002-09-12 | Xenova Research Limited | Papillomavirus vaccines |
| WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
| WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
| WO2005032586A1 (en) * | 2003-09-29 | 2005-04-14 | Merck & Co., Inc. | Optimized expression of hpv 45 l1 in yeast |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
-
2006
- 2006-04-24 EP EP06724609A patent/EP1877086A2/en not_active Ceased
- 2006-04-24 SG SG201000794-6A patent/SG159525A1/en unknown
- 2006-04-24 US US11/912,687 patent/US20090181052A1/en not_active Abandoned
- 2006-04-24 JP JP2008508156A patent/JP2008539184A/ja active Pending
- 2006-04-24 MX MX2007013472A patent/MX2007013472A/es unknown
- 2006-04-24 CA CA002606092A patent/CA2606092A1/en not_active Abandoned
- 2006-04-24 WO PCT/EP2006/003918 patent/WO2006114312A2/en not_active Ceased
- 2006-04-24 EA EA200702079A patent/EA013326B1/ru not_active IP Right Cessation
- 2006-04-24 AR AR20060101619A patent/AR054259A1/es not_active Application Discontinuation
- 2006-04-24 AU AU2006239422A patent/AU2006239422A1/en not_active Abandoned
- 2006-04-24 KR KR1020077027497A patent/KR20080005585A/ko not_active Ceased
-
2007
- 2007-10-11 NO NO20075194A patent/NO20075194L/no not_active Application Discontinuation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
| WO2002070004A2 (en) * | 2001-03-07 | 2002-09-12 | Xenova Research Limited | Papillomavirus vaccines |
| WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
| WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
| WO2005032586A1 (en) * | 2003-09-29 | 2005-04-14 | Merck & Co., Inc. | Optimized expression of hpv 45 l1 in yeast |
Non-Patent Citations (6)
| Title |
|---|
| DA SILVA D. M. ET AL.: "Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 23, 4 July 2003 (2003-07-04), pages 3219-3227, XP004429731 ISSN: 0264-410X, page 3225, column 2; figure 2 * |
| DE VILLIERS E-M ET AL.: "Classification of papillomaviruses", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 324, no. 1, 20 June 2004 (2004-06-20), pages 17-27, XP004512668 ISSN: 0042-6822, cited in the application, the whole document * |
| KOWALCZYK D. W. ET AL.: "Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 25-26, 14 May 2001 (2001-05-14), pages 3583-3590, XP004238957 ISSN: 0264-410X, abstract * |
| QIAN JIAHUA ET AL.: "Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 118, no. 12, 15 June 2006 (2006-06-15), pages 3022-3029, XP002396698 ISSN: 0020-7136, published online 19 January 2006, abstract * |
| VAN DER BURG S. H. ET AL.: "Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens", VACCINE, BUTTERWORTH SCIENTIFIC, GUILDFORD, GB, vol. 19, no. 27, 14 June 2001 (2001-06-14), pages 3652-3660, XP004241783, ISSN: 0264-410X, abstract -& WO 02/070004 A2 (XENOVA RES LTD [GB]; LEIDEN UNIVERSITY MEDICAL CT [NL]; HICKLING JULIA), 12 September 2002 (2002-09-12) * |
| VILLA L. L. ET AL.: "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 5, 7 April 2005 (2005-04-07), pages 271-278, XP004870902, ISSN: 1470-2045, published online 7 April 2005, the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006114312A3 (en) | 2007-04-05 |
| EP1877086A2 (en) | 2008-01-16 |
| AU2006239422A1 (en) | 2006-11-02 |
| AR054259A1 (es) | 2007-06-13 |
| JP2008539184A (ja) | 2008-11-13 |
| MX2007013472A (es) | 2008-04-02 |
| SG159525A1 (en) | 2010-03-30 |
| EA200702079A1 (ru) | 2008-04-28 |
| KR20080005585A (ko) | 2008-01-14 |
| CA2606092A1 (en) | 2006-11-02 |
| US20090181052A1 (en) | 2009-07-16 |
| WO2006114312A2 (en) | 2006-11-02 |
| NO20075194L (no) | 2008-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101361769B1 (ko) | Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신 | |
| JP2012102132A (ja) | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン | |
| EA013326B1 (ru) | Вакцина | |
| RU2420313C2 (ru) | Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52 | |
| EA013325B1 (ru) | Вакцина | |
| US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
| US7858098B2 (en) | Vaccine | |
| US20050053623A1 (en) | Novel vaccination | |
| CN101217975A (zh) | 疫苗 | |
| BRPI0610032A2 (pt) | uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit | |
| HK1085378B (en) | Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KZ RU |